ACM
SYRE icon

Aquatic Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Aquatic Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.24M Buy
+25,222
New +$1.84M 0.08% 339
2025
Q2 		– Sell
-12,903
Closed -$208K – 1526
2025
Q1 		$208K Buy
12,903
+1,136
+10% +$23.6K 0.01% 922
2024
Q4 		$274K Buy
+11,767
New +$345K 0.01% 865
2024
Q3 		– Sell
-11,800
Closed -$277K – 1528
2024
Q2 		$277K Buy
+11,800
New +$398K 0.01% 666

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Aquatic Capital Management's SYRE Position: Q2 2026 in Review

Aquatic Capital Management opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 25,222 shares worth $2.24M. The stake represents 0.08% of the portfolio and ranks #339 among its holdings. This is a return to the name: Aquatic Capital Management previously reported a position in SYRE as recently as Q1 2025.

Aquatic Capital Management first reported a position in SYRE in Q2 2024 and has held it in 4 quarters since. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Aquatic Capital Management held 25,222 shares of Spyre Therapeutics worth $2.24M as of Q2 2026.
  • Spyre Therapeutics was a new Aquatic Capital Management position in Q2 2026.
  • Spyre Therapeutics made up 0.08% of Aquatic Capital Management's portfolio in Q2 2026, its #339 holding.
  • Aquatic Capital Management first reported a position in Spyre Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.